Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587985 | 0.81 | KDM4C (0.33) | GABRA1GABRB2 | |
| SCHEMBL20644923 | 0.80 | LOXL2 (0.36) | LOXL2 | |
| Hydrochloric Acid SCHEMBL30122011 | 0.79 | LOXL2 (0.35) | LOXL2 | |
| Hydrochloric Acid SCHEMBL20446381 | 0.79 | LOXL2 (0.35) | LOXL2 | |
| SCHEMBL1741193 | 0.77 | CYP2A6 (0.38) | LOXL2GABRA1GABRB2 | |
| SCHEMBL9447458 | 0.77 | GABRA1 (0.38) | GABRA1GABRB2 | |
| SCHEMBL1400243 | 0.77 | GABRA1 (0.59) | GABRA1GABRB2 | |
| SCHEMBL15800403 | 0.77 | SLC6A4 (0.36) | GABRA1GABRB2 | |
| SCHEMBL12385452 | 0.77 | LOXL2 (0.45) | LOXL2ADRA2C | |
| SCHEMBL7898466 | 0.77 | CYP2A6 (0.45) | LOXL2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6392083-B2 | REACTING A CYANOBENZYLAMINE WITH AN ACID SELECTED FROM HYDROCHLORIC ACID, SULFURIC ACID, ACETIC ACID, TRIFLUROACETIC ACID AND PROPIONIC ACID TO FORM A SALT HAVING HIGH BULK DENSITY | SHOWA DENKO K.K. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20010049453-A1 | Process for producing salts of cyanobenzylamines | SHOWA DENKO K.K. | 2001-12-06 | — | — | US | disclosed |
| EP-1151989-A1 | PROCESS FOR PRODUCING SALT OF CYANOBENZYLAMINE OR DERIVATIVE | Showa Denko K.K. (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049453-A1 | Process for producing salts of cyanobenzylamines | MMAB, BLVRB, SLC6A12 | LOXL2 2213/4885GABRA1 1082/4885GABRB2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.